MedTech Breakthrough, an independent organisation that recognises the top companies and solutions in the global health and medical technology market, has selected Elsevier’s Via Oncology as the winner of its ‘Best Computerized Decision Support Solution’ award in the 2019 MedTech Breakthrough Awards program.
Elsevier’s Via Oncology is a national leader in cancer care management and clinical decision support that incorporates advanced technology to identify and match eligible patients with clinical trial opportunities. Despite the rapidly growing rate of cancer worldwide, recruitment for clinical trials has become increasingly challenging, with fewer than 1 in 20 adults with cancer enrol in clinical trials.
Via Oncology aims to close this gap between cancer patients and clinical trial enrolment, as well as overall cancer care, by providing computerized decision support to increase enrolment rates and help ensure patients receive access to the most current and targeted therapies in development.
The MedTech Breakthrough Awards aim to honour excellence and recognise the innovation, hard work and success in a range of health and medical technology categories, including Robotics, Clinical Administration, Telehealth, Patient Engagement, Electronic Health Records (EHR), mHealth, Medical Devices, Medical Data and many more. This year’s program attracted more than 3,500 nominations from over 15 different countries throughout the world.
Elsevier announced in January 2018 that it had acquired Pittsburgh, Pennsylvania-based Via Oncology, a former subsidiary of UPMC (University of Pittsburgh Medical Center), one of the nation’s leading integrated healthcare delivery and financing systems.
Brought to you by Scope e-Knowledge Center, a trusted global partner for digital content transformation solutions - Abstracting & Indexing (A&I), Knowledge Modeling (Taxonomies, Thesauri and Ontologies), and Metadata Enrichment & Entity Extraction.
